Materiovigilance After Urinary Incontinence or Prolapse Surgery

NCT ID: NCT03052985

Last Updated: 2023-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

19000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-02-14

Study Completion Date

2033-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observatory of Materiovigilance After Surgery of Urinary Incontinence or Prolapse in Women Implantable medical devices (meshes) used in pelvic organ prolapse surgery (genital prolapse, rectal prolapse), or incontinence surgery may be source of severe complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RATIONAL Implantable medical devices (meshes) used in pelvic organ prolapse surgery (genital prolapse, rectal prolapse), or incontinence surgery may be source of severe complications.

MAIN OBJECTIVE Estimate the incidence of severe complications during or after surgery of urinary incontinence or pelvic organ prolapse in adult women depending on the type of surgery performed.

SECONDARY OBJECTIVES Estimate the incidence of severe complications after urinary incontinence or prolapse surgery as a function of time since surgery.

Compare the incidence rates of severe complications considering the type of procedure (with or without mesh, vaginal or laparoscopic, etc.), comorbidities, mesh type, surgeon experience, and surgical volume centre.

Report the health and satisfaction of operated women. Estimate the risk of revision surgery for failure or recurrence.

MAIN OUTCOME Per- and post-operative complications (less than 12 months after surgery), or late (after 12 months) severe (grade III or higher according to the Clavien-Dindo classification)

OTHER OUTCOMES Time lapse of occurrence of severe complications Surgical recovery for failure or recurrence Health and perceived improvement (OMS, EQ5D, an PGI-I questionnaires)

DESIGN Prospective multicentre cohort allowing the constitution and analysis of an observatory off surgery for genital prolapse, rectal prolapse and urinary stress incontinence in women.

INCLUSION CRITERIA

* Operated for urinary incontinence, genital prolapse, or rectal prolapse in one of the centres participating in the observatory
* 18 years old or more.

SUBJECTS NUMBER Estimated at 3000 per year during 5 years in 18 participating centres

STUDY LENGTH Duration of the inclusion period: 2 years with the initial grant from ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé, French Medicines and Healthcare Products Regulatory Agency), after new funding by ANSM 5 years of inclusion in total.

Duration of participation of subjects: 2 years with grant from ANSM, after the new funding by ANSM 10 years.

Total duration of the study: 3 years with the grant from ANSM, 15 years with the new funding.

ANALYSIS PLANNED The one-year analysis will be based on multivariate logistic regression analysis (considering confounding factors). The 10-year (or intermediate-term) analysis will use survival analysis methods to account for delays in complications: Kaplan-Meier curves; Model of Cox proportional hazards.

PERSPECTIVES The observatory should make it possible to precise the tolerance and the short- and long-term consequences of the use of these implantable devices (meshes) in pelvic organ prolapse or incontinence surgery in women and to specify the risk factors for severe complications.

The observatory will enable to make comparisons between the different types of meshes and different surgical procedures, and to identify those that may present problems.

Clinical practice recommendations may be issued as well as standards for marketing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pelvic Organ Prolapse Rectal Prolapse Urinary Stress Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

urinary incontinence, pelvic organ or rectal prolapse surgery

The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Operated for urinary incontinence, pelvic organ prolapse, or rectal prolapse in one of the centres participating in the observatory
* 18 years old or more.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Agence Nationale de sécurité du Médicament

OTHER

Sponsor Role collaborator

Poitiers University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xavier FRITEL, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Poitiers University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre l'Avancée - Clinique Axium

Aix-en-Provence, , France

Site Status

C.H.U. d'Angers

Angers, , France

Site Status

CHRU de Besançon

Besançon, , France

Site Status

Centre Hospitalier de Béthune

Béthune, , France

Site Status

CHU de Bordeaux

Bordeaux, , France

Site Status

CHU Caen

Caen, , France

Site Status

Centre Hospitalier Camille Guérin

Châtellerault, , France

Site Status

Hôpital Antoine-Béclère

Clamart, , France

Site Status

Chu Estaing

Clermont-Ferrand, , France

Site Status

Centre Hospitalier de Dunkerque

Dunkirk, , France

Site Status

Polyclinique d'Hénin-Beaumont

Hénin-Beaumont, , France

Site Status

Hopital La Rochelle- Ré- Aunis

La Rochelle, , France

Site Status

CHU Lille

Lille, , France

Site Status

Hôpital St Vincent De Paul

Lille, , France

Site Status

CHU de Limoges

Limoges, , France

Site Status

Hospices Civils de Lyon

Lyon, , France

Site Status

Clinique BEAUSOLEIL

Montpellier, , France

Site Status

CHRU de NANCY

Nancy, , France

Site Status

CHU Nantes

Nantes, , France

Site Status

CHRU Carémeau

Nîmes, , France

Site Status

La Pitié-Salpêtrière

Paris, , France

Site Status

Hôpital Bichat

Paris, , France

Site Status

Groupe Hospitalier Diaconesses Croix Saint-Simon

Paris, , France

Site Status

Centre briochin d'Urologie

Plérin, , France

Site Status

CHI Poissy-St-Germain

Poissy, , France

Site Status

CHU de Poitiers

Poitiers, , France

Site Status

CHU de Reims

Reims, , France

Site Status

CHU Strasbourg

Strasbourg, , France

Site Status

Hopital Foch

Suresnes, , France

Site Status

Clinique UROVAR

Toulon, , France

Site Status

CHU de Toulouse

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Carter E, Johnson EE, Still M, Al-Assaf AS, Bryant A, Aluko P, Jeffery ST, Nambiar A. Single-incision sling operations for urinary incontinence in women. Cochrane Database Syst Rev. 2023 Oct 27;10(10):CD008709. doi: 10.1002/14651858.CD008709.pub4.

Reference Type DERIVED
PMID: 37888839 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-A01868-43

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.